const questions = [
  {
    text: 'A 65-year-old male with a history of chronic heart failure with reduced ejection fraction (HFrEF) is currently on lisinopril, carvedilol, and furosemide. His recent echocardiogram shows an ejection fraction of 30%. Which of the following medications should be added to his regimen to improve mortality?',
    options: [
      'A. Digoxin',
      'B. Spironolactone',
      'C. Amlodipine',
      'D. Hydralazine'
    ],
    correctAnswer: 1,
    explanation:
      'Spironolactone is an aldosterone antagonist that has been shown to reduce mortality in patients with HFrEF. It is recommended for patients with an ejection fraction of 35% or less who remain symptomatic despite optimal therapy with ACE inhibitors and beta-blockers.',
    topic: 'Drugs in Heart Failure'
  },
  {
    text: 'A 72-year-old female with a history of heart failure with preserved ejection fraction (HFpEF) is being evaluated for medication management. Which of the following classes of drugs has shown a mortality benefit in patients with HFpEF?',
    options: [
      'A. Angiotensin receptor-neprilysin inhibitors (ARNIs)',
      'B. Beta-blockers',
      'C. Mineralocorticoid receptor antagonists',
      'D. None of the above'
    ],
    correctAnswer: 3,
    explanation:
      'Currently, there is no class of drugs that has shown a definitive mortality benefit in patients with HFpEF. Management focuses on symptom control and treatment of comorbidities.',
    topic: 'Drugs in Heart Failure'
  }
];

console.log(questions[1]);
